Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Airway Components

Home Resources Airway Components

Airway Components of Asthma Assessment

Airways assessment should include a confirmation of diagnosis and an objective measurement of variable expiratory airflow obstruction. This may be performed in conjunction with a bronchial provocation test, under controlled conditions. However, it should be noted that some people with severe asthma may exhibit minimal reversibility. This assessment should also include consideration of acute exacerbation history and risks and airway inflammation (e.g. sputum assessment or FeNO measurement. Also see Diagnosis & Assessment.

Airflow obstruction / limitation
Bronchodilator reversibility
Dyspnoea
Airway inflammation
Frequent chest infection
Pathogen colonisation
Mucus hypersecretion
Lung structure abnormality
Exercise intolerance
Airflow obstruction / limitation
Spirometry assessment – Spirometry should be assessed for all individuals with asthma. Airflow limitation is indicated when FEV1/FVC ratio <70% and FEV1 <80% predicted, or based on comparison to agreed standards. For more information see Basic Lung Function & Bronchial Challenge Tests. The National Asthma Council Australia website provide useful resources and tools on how to perform spirometry.
Bronchodilator reversibility
Spirometry assessment – Measurement of spirometry before and after administration of a rapid onset bronchodilator is considered reversible if FEV1 increases by ≥200mL or ≥12%. Failure to demonstrate reversibility does not necessarily rule out a diagnosis of asthma, particularly in the severe asthma population. For more information see Diagnosis – Basic Lung Function
Dyspnoea
Modified Medical Research Council Scale (mMRC) – The mMRC scale is used to assess functional limitation due to dyspnoea (Mahler et al. 1988, Bestall et al. 1999). Participants grade their level of breathlessness symptoms using this 5-item scale. The scale ranges from 0-4, with 0 representing the least degree of functional limitation due to dyspnoea. A score equal to or greater than 2 indicates dyspnoea as a significant problem (Celli et al. 2005).

Dyspnoea Severity Index – Assesses upper airway symptoms and treatment follow-up. Consists of a 10-item 5-point Likert scale (Gartner-Schmidt et al. 2014).  Score > 10 suggestive of abnormal upper airway dyspnoea. Good reliability and discriminant validity reported, but has not been reported as a diagnostic tool and not specific for VCD. For access email: gartnerschmidtjl@upmc.edu

Dyspnoea-12 – The Dyspnoea-12 is a 12-item assessment tool that provides an overall score of dyspnoea magnitude (scored 0-36, higher score indicate more severe dyspnoea) as well as two sub-scores: i) physical component and ii) affective component. It has been validated in a range of conditions including asthma, it is simple and quick to use. It has a minimal clinically important difference of 3 points (calculated for COPD and lung cancer) (Yorke et al. 2010). More information is available here – http://thorax.bmj.com/content/65/1/21.

Download the Dyspnoea-12 questionnaire here.

Airway inflammation
Induced sputum cell counts – Characterisation of immune cell proportions in induced sputum samples can provide insights into the type of airway inflammation and possible underlying disease mechanisms. Inflammation may be defined as neutrophilic (≥61% neutrophils), eosinophilic (≥3% eosinophils), paucigranulocytic or mixed granulocytic inflammatory phenotypes based on microscopy assessment (Simpson et al. 2006).

For more information see Diagnosis – Sputum

Resources to guide assessment & quantification – A step-by-step guide for induced collection, processing and analysis is available on from the European Respiratory Society.

Frequent chest infection
Antibiotic courses – Requirement for ≥2 antibiotic courses in 12-months for infective bronchitis.
Pathogen colonisation
Sputum culture – Presence of a recognised pathogen in sputum culture.

Allergic bronchopulmonary aspergillosis (ABPA) – ABPA is a hypersensitivity reaction to Aspergillus fungal species. Diagnosis requires chest X-ray or high-resolution CT, skin prick test to Aspergillus, Aspergillus detection in blood or sputum culture and assessment of IgE levels.

For ABPA diagnostic criteria click here

Mucus hypersecretion

The lung normally produces approximately 20 – 30 mL of mucus per day. When an excess amount is produced and needs to be expectorated, it is termed sputum. Can be assessed based on the question of whether a patient has produced a volume ≥25mL of sputum production daily in the past week in the absence of an infection (Rabe et al. 2007).

The Bronchiectasis Toolbox provides additional information about mucus assessment based on volume and colour.

Lung structure abnormality
See Diagnosis & Assessment – Imaging (Computed tomography)

See Diagnosis & Assessment – Bronchoscopy

Exercise intolerance
6-Minute Walk Test (6MWT) – The 6MWT is a sub-maximal exercise test used to measure exercise capacity.  Individuals are asked to walk as far and as fast as they can for a 6-minute period, by.  A change in the distance walked in the 6MWT can be used to assess for treatment efficacy (Holland et al. 2014).

A protocol for conducting 6MWTs  can be found at: https://pulmonaryrehab.com.au/patient-assessment/assessing-exercise-capacity/six-minute-walk-test/

Previous
Next

Last Updated on November 15, 2022

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Clinic Recommendations
  • Infographics
  • Asthma Assessment Resources
  • Systematic & Multidimensional Assessment Resources
    • Airway Components
    • Comorbidity Components
    • Risk Factor Components (Including Self-Management)
  • Translation & Implementation
  • Case Studies
  • Presentations
  • Videos
  • Relevant Links
  • Key References

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia